Hasty Briefsbeta

Bilingual

OSBPL3-driven sterol metabolic reprogramming promotes oncogenic signaling and therapeutic resistance in pancreatic cancer - PubMed

3 days ago
  • #Pancreatic Cancer
  • #Therapeutic Resistance
  • #OSBPL3
  • OSBPL3 is highly expressed in pancreatic cancer (PDA) and associated with poor prognosis.
  • Increased OSBPL3 expression enhances PDA cell proliferation, stemness, metastasis, and chemoresistance.
  • OSBPL3 modulates PDA malignancy via the NOTCH signaling pathway.
  • OSBPL3-driven sterol metabolic reprogramming enriches cholesterol esters and steroid metabolites.
  • Inhibition of cholesterol synthesis enzymes reduces NOTCH pathway activity and stemness in PDA.
  • Targeting OSBPL3 or its signaling could improve therapeutic efficacy in PDA patients.